ArticleAlimentary pharmacology & therapeutics2022

Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.

Christian P Selinger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.